Abstract
The purpose of this study was to determine the magnitude of vasodilation by CVT-3146 in different vascular beds and to compare it with that by adenosine in conscious dogs. Intravenous bolus injections of CVT-3146 (0.1–2.5 μg/kg) or adenosine (10–250 μg/kg) caused a dose-dependent increase in the coronary blood flow (CBF) and a dose-dependent decrease in the late diastolic coronary resistance. Although the maximal increase in CBF response to the two drugs was not significantly different, the ED50 of CVT-3146 and adenosine were 0.45 ± 0.07 μg/kg and 47 ± 7.77 μg/kg, respectively. The highest dose of CVT-3146 caused a much longer coronary vasodilation than the highest dose of adenosine. There were no significant differences in increases in cardiac output induced by higher doses of CVT-3146 or adenosine. Most importantly, CVT-3146 resulted in a smaller decrease in total peripheral resistance (TPR) compared to that seen with adenosine. In addition, CVT-3146 yielded a smaller increase in the lower body flow (LBF) than adenosine. Adenosine also caused dose-dependent renal vasoconstriction, whereas CVT-3146 did not affect the renal blood flow. The administration of CVT-3146 or adenosine caused a dose-dependent vasodilation in the mesentery, which was not significantly different from each other. In summary, CVT-3146 is a 100-fold more potent coronary vasodilator than adenosine. CVT-3146 causes smaller decreases in TPR and smaller increases in LBF than those induced by adenosine, indicating that it is more selective for coronary than peripheral vasodilation. Furthermore, CVT-3146 did not cause renal vasoconstriction. These features make CVT-3146 a better candidate for pharmacologic stress testing.
Footnotes
-
Supported by CV Therapeutics, National Institutes of Health Grants P0-1-43023, R0-1-HL50142, and HL 61290 (to T.H.H.) and the German Research Foundation (to A.L.)
-
DOI: 10.1124/jpet.103.053306.
-
ABBREVIATIONS: CBF, coronary blood flow; AdoR, adenosine receptor; CO, cardiac output; LBF, lower body flow; MBF, mesenteric blood flow; RBF, renal blood flow; MAP, mean arterial pressure; LDCR, late diastolic coronary resistance; LVR, lower body vascular resistance; MVR, mesenteric vascular resistance; RVR, renal vascular resistance; HR, heart rate; TPR, total peripheral resistance.
- Received May 6, 2003.
- Accepted July 8, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|